list of glp-1 agonists Clinical Trials Evaluating the Cardiovascular Efficacy and Market Overview: GLP-1 Agonists and
Description
Although we sought to minimize this selection bias by including all eligible participants, unmeasured confounding must be considered
Nevertheless, GLP-1 presented a rather ephemeral circulatory half-life, lasting a mere 12 min, due to the rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-4), which markedly limits its biological efficacy [3,4,5]
However, history suggests that there is promise for greater access
June 4, 2021
& Lu, J
